This most up-to-date twist from the Lykos Therapeutics saga threatens a major overhaul of the organization’s strategy and route, with Musk ally and billionaire investor Antonio Gracias appearing to wish to acquire the organization again toward its nonprofit drug improvement roots and a more Doblinite philosophy.“There’s destined to be lots of